Product：Saxenda Liraglutide Injection
Place of origin：Denmark

– The only GLP-1 analogue approved by the FDA and EMA (European Drug Administration) for weight management in Hong Kong as an adjunct to low calorie diet and physical activity
– Heavy patient weight loss and effective maintenance
– Significant and sustained weight loss in a one-year study, while improving cardiac metabolic risk factors: 9 out of 10 patients achieved weight loss, and 1 of 3 patients lost weight Up to >10%
– Patients have significant improvements in cardiovascular metabolism and risk factors
– The first weight-loss drug developed using the diabetes drug liraglutide, with a glucose concentration-dependent hypoglycemic effect and beta cell protection, can play the following roles:
– Increase glucose-dependent insulin secretion; inhibit glucagon secretion and increase glucose clearance
– Delay gastric emptying and induce satiety, suppress appetite
– Simply put, it is to reduce the hunger by adjusting the appetite, delay the feeling of fullness, and people become thinner.
– Suppresses appetite, is prone to satiety, and has good weight loss
– The effect of reducing body fat is obvious
– Effectively inhibit the incidence of diabetes, stroke, myocardial congestion, etc.
– For visceral fat (all body)
– Can also target central obesity (waist circumference)